Marathon Medical wins inclusion of the geko™ device on its Veterans Administration Federal Supply Schedule Contract

What Kind of Equipment is Used to Analyze DNA?

Below are some of a few basic processes followed throughout DNA testing. The general procedure entails:  • Isolating DNA from a sample containing the needed...

mJOULE Launches in the United Kingdom Reports Sciton

"Sciton is dedicated to worldwide support and growth. We continue to demonstrate our commitment to developing high quality devices and marketing efforts for our physician and medspa partners worldwide." says Lacee J. Naik, Vice President of Marketing and Public Relations.

FDA Issues Draft Guidance on Remanufacturing and Discussion Paper Seeking Feedback on Cybersecurity Servicing of Medical Devices

With this in mind, the FDA is issuing today's draft guidance to help clarify whether activities performed on medical devices are likely remanufacturing as well as a discussion paper on cybersecurity servicing of devices.

Marathon Medical Inc. is a distribution partner to Sky Medical Technology.

The wearable, clinically proven geko™ is a small, battery powered, disposable, neuromuscular electro-stimulation device, that is applied non-invasively to the skin over the common peroneal nerve at the side of the knee. Small electrical pulses gently stimulates the nerve, once every second, activating the calf and foot muscle pumps resulting in increased blood flow in the deep veins of the calf, at rate equal to 60% of continuous walking without the patient having to move. The increase in blood flow prevents venous thromboembolism (VTE – blood clots)[3], reduces pre-operative trauma-based swelling and prevents and treats the build-up of post-operative swelling.

The Contract award number #36F79718D0321 enables the VA and other federal organizations to purchase the FDA-cleared geko™ device at pre-approved pricing via the Marathon Medical Federal Supply Schedule (FSS) contract, or via the GSA Advantage Online Catalog. Additionally the Department of Defense has included the product on DAPA contract number #SP0200-13-H-0003.

“Adding the geko™ device to our supply schedule to help the VA hospitals prevent Venous Thromboembolism (VTE) and manage post-operative and trauma-based swelling, makes perfect sense,” says Jon Landis, COO, Marathon Medical. “Blood clots affect more than 900,000 American citizens each year, and 3 in 10 people who suffer a blood clot will have another episode within 10 years. Edema, the medical term for swelling, a huge and until now more silent burden, with few tools to address the complication, can delay surgical fixation, impede wound closure, decrease muscle strength and stall rehabilitation. We are therefore extremely proud to provide federally-operated hospitals access to an innovation that can help address these significant medical challenges.”

“We share in this excitement,” says Bernard Ross, Sky Founder and CEO. “The VA is the largest Integrated health network in the USA, treating in excess of 9 million veterans annually, at 171 VA hospitals and 1,454 health care facilities. We plan to serve this health system alongside Marathon to grow geko™ device awareness and market access. Our partnership with Marathon and the inclusion of the geko™ device on the FSS contract, enables our commitment to help those who serve and have served their country and their families. It is our hope that that we can make a positive impact on the lives of veterans to prevent life threatening blood clots and to manage swelling complications related to surgery and trauma.”

  • To increase local blood circulation.
  • For immediate post-surgical stimulation of the calf muscles to prevent venous thrombosis.
  • Stimulation of the calf muscles to prevent venous thrombosis in non-surgical patients at risk for venous thromboembolism.
  • For the reduction of edema.

In the USA the geko™ device is cleared for the following indications:

spot_img

DON'T MISS

Hyperfine Adds Medtech Leader and Visionary Scott Huennekens as Executive Chairman

Mr. Huennekens’ public boards include Chairman of Acutus Medical (IPO August 2020); Chairman of Envista (IPO September 2019); and board member of Nuvasive. He also serves as a board member and past Chairman of the Medical Device Manufacturer’s Association (MDMA).

One Drop Reports Carrie Siragusa, CPA Appointed VP of Commercial Strategy, Biosensor

Formerly Head of Innovation and Diabetes Portfolio at Sanofi, Siragusa will be part of a team bringing a multi-analyte dermal sensor (biosensor) with continuous health sensing capabilities to market with a mission to provide broader access to continuous glucose monitoring.

Barbara Moorhouse Appointed as Medica Non-Executive Director

Barbara has extensive business and management experience in the private, public, and regulated sectors.

Subscribe to Medical Device News Magazine here.

Related Articles